CLL Preceptorships

The management of chronic lymphocytic leukemia (CLL) has undergone dramatic changes over the previous two decades with the introduction of multiple new agents and new combination therapies1. Better understanding of prognostic factors has helped tailor therapy for individual patients, and work continues to identify optimal therapy for each patient2.

Expanding the treatment option comes along with a paradigm shift regarding therapeutic objectives towards improved long-term outcomes in most CLL patients3.

The expansion of the therapeutic armamentarium to treat CLL implicit growing complexity to find the optimal treatment for each patient taking into consideration the line of therapy, genetic risk factors, coexisting medical conditions and also taking into account the later treatment sequence4.

Considering these exciting developments, we are happy to provide the opportunity of CLL preceptorships to discuss latest results and approaches to manage the disease with leading experts in CLL.

1Burger, N Engl J Med 2020; 383:460-73

2Awan et al., Am Soc Clin Oncol Educ Book 2020; 40:1-10

3Brandner et al., Am Soc Clin Oncol Educ Book 2019; 39:487-498

4Hallek et al., Lancet 2018; 391 (10129): 1524-1537

Organizing Secretariat


help desk